Cosmetic neuropeptide
Argireline
Argireline is the cosmetic peptide acetyl hexapeptide-8; in human cadaver skin 0.22% of the applied dose stayed in the stratum corneum and none was detected in the dermis, against the app's 95% bioavailability.1
Argireline after one dose: 50% at ~4 h, 25% at 8 h, 12.5% at 12 h.
Drawn from the half-life in the app's model, ~4 h. The model's figures
- Compound
- Argireline
- Symbol
- ARG
- Family
- Cosmetic and copper peptides
- Parts
- 12
- References
- 14
- Checked
- Last reviewed . Sources are listed below.
Overview
Argireline is the trade name of a six-amino-acid peptide, Ac-EEMQRR-NH2, described by Blanes-Mira and colleagues (Universidad Miguel Hernández, Alicante) in the International Journal of Cosmetic Science in 2002.2 Its ingredient name is acetyl hexapeptide-8, which the Cosmetic Ingredient Review Expert Panel reports "to function as a skin conditioning agent - miscellaneous in cosmetics".3 The app files it as a topical cosmetic peptide applied at roughly 5–10% serum concentration and grades the evidence as moderate, while describing that evidence as small cosmetic trials. The human evidence summarised below comes from one randomised wrinkle trial in 60 people (Wang and colleagues, American Journal of Clinical Dermatology, 2013), a 2002 report in healthy women volunteers (Blanes-Mira and colleagues), two registered blepharospasm trials from the US National Institutes of Health, two registered skin trials with no posted results (Mahidol University, 70 enrolled, and UC Davis, 14 enrolled), and a retrospective case series.4,2,8,9,7,11,10 A 2025 review of the peptide's skin permeability and efficacy states that "the ability of AH-8 to reach neuromuscular junctions remains uncertain".5
How it works
Sources in this part
Wang and colleagues describe argireline as "patterned from the N-terminal end of the protein SNAP-25" and report that it "is reported to inhibit vesicle docking by preventing formation of the ternary SNARE complex and by interfering in catecholamine release".4 In the 2002 report from Blanes-Mira and colleagues, argireline "significantly inhibited neurotransmitter release with a potency similar to that of BoNT A, although as expected, it displayed much lower efficacy than the neurotoxin".2 The record attributes this to "interference of the hexapeptide with the formation and/or stability of the protein complex that is required to drive Ca(2+)-dependent exocytosis".2 The 2025 review notes that "the precise biological mechanisms underlying these effects" in people, "particularly the peptide's ability to inhibit muscle contraction when applied topically", "remain incompletely understood".5 The mechanism is therefore a laboratory finding and a proposal, and none of the cited sources shows it operating in the skin of treated people.5
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~4 h
- Bioavailability
- 95%
- Typical dose
- 5–10%
- Route
- Topical
- Time to peak
- ~0.5 h
The second column of the table holds the app's figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~4 h | No half-life figure for argireline was returned by the searches5 |
| Bioavailability | 95% | 0.22% of the applied dose in the stratum corneum of human cadaver skin and 0.01% in the epidermis after 24 hours; no peptide detected in the dermis or the buffer beneath the skin (in vitro)1; a different in vitro study described in the 2025 review reports 30% of the applied amount of a 10% O/W emulsion in the receptor fluid after 2 h5 |
| Time to peak | ~0.5 h | No time-to-peak figure reported in the sources read5 |
| Duration | 12 h | No duration-of-effect figure reported in the sources read5 |
| Route | Topical | Applied to skin as creams, gels, lotions or emulsions in the trials below4,7,8 |
The app's own notes say systemic tracking does not apply and that the modelled curve does not reflect how the compound works.
Deeper analysis: skin penetration in vitro (Kraeling and colleagues, 2015)
Kraeling and colleagues, at the US Food and Drug Administration's Office of Applied Research and Safety Assessment, reported in Cutaneous and Ocular Toxicology in 2015 on commercially available acetyl hexapeptide-8 applied to "hairless guinea pig (HGP) and human cadaver skin assembled into in vitro diffusion cells".1 An oil-in-water emulsion containing 10% of the peptide was applied "at a dose of 2 mg/cm(2)" and, after a 24-hour exposure, the surface was washed.1 The authors report that "the majority of the Ac-EEMQRR-amide was washed from the surface of both HGP and human skin".1 In the hairless guinea pig skin 0.54% of the applied dose was in the stratum corneum, against 0.22% in human skin, and the epidermis held 0.01% in both.1 No peptide was detected in the dermis or the receptor buffer, and "no hexapeptide metabolite" was detected in any layer.1 The PubMed record lists a research-support publication type and gives no funding statement, author ties to a manufacturer, or limitations section; the experiment used excised skin, so it measures penetration into skin layers, not blood levels in people.1 The authors give the stated reason for the work: "a concern that peptides in cosmetic creams marketed as anti-aging/anti-wrinkle may penetrate into the deep layers of the skin and potentially stimulate biological activity".1
Hoppel and colleagues (University of Vienna), in the European Journal of Pharmaceutical Sciences in 2015, note that the peptide's "skin penetration is sparsely studied and controversially discussed" and report, in porcine ear skin and Franz diffusion cells, that "a multiple water-in-oil-in-water (W/O/W) emulsion can significantly increase penetration of AH-8 into porcine skin compared to simple O/W and W/O emulsions".6 The 2025 review adds that "due to its hydrophilic nature and relatively large molecular size, AH-8 faces limited permeability through the lipophilic stratum corneum".5
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Blanes-Mira and colleagues, Int J Cosmet Sci 20022 | Skin topography analysis; sponsor and group size not given in the record | Healthy women volunteers | 10% hexapeptide in an oil-in-water emulsion; 30 days | Wrinkle depth reduced "up to 30%"; the record names no placebo or control group2 |
| Wang and colleagues, Am J Clin Dermatol 20134 | Randomised, placebo-controlled, 3:1 | 60 Chinese subjects with peri-orbital wrinkles | Argireline or placebo twice daily for 4 weeks (concentration not given in the record) | Total anti-wrinkle efficacy 48.9% with argireline against 0% with placebo; roughness parameters decreased with argireline (p < 0.01)4 |
| Mahidol University, NCT01381484, registered 20117 | Randomised, triple-masked, placebo gel; entry lists no results | 70 healthy women aged 35 to 45 with periorbital wrinkles | 10% Argireline gel twice daily; 3 months | Results not posted in the registry entry7 |
| NINDS, NCT00942851, results posted 20128 | Randomised, triple-masked, placebo cream; phase 1/2 | 24 enrolled with blepharospasm and a stable response to botulinum toxin injections | 0.005% AH-8 cream twice daily on the eyelids; up to 7 months | Time for the rating scale to return to baseline 3.71 months (SD 1.48, n=12) with AH-8 against 3.03 (SD .23, n=11) with placebo; 4 of 24 had eyelid irritation, 2 in each arm; one placebo participant left for unrelated personal problems8 |
| NINDS, NCT01750346, terminated, results posted 20169 | Randomised, double-masked, placebo cream; phase 2; terminated | 8 enrolled with primary blepharospasm (24 planned) | 0.025% or 0.05% AH-8 or placebo, twice daily; 2-month primary outcome | Rating scale at 2 months: 6 (0.05%, n=2), 7 (0.025%, n=2), 4.33 (placebo, n=3); one serious event in each of the 0.05% and placebo arms9 |
| Palmieri and colleagues, Clin Ter 202010 | Spontaneous, anecdotal, retrospective; no control group | 26 patients with skin disorders, scars or wrinkles | Gel cream with 10% acetyl hexapeptide-8 | Skin quality parameters improved; no allergic reactions documented10 |
The registry lists Mahidol University as lead sponsor and Pacific Health Foundation as a collaborator, and names the 10% gel tested as La jolie gel from Pacific health care, Thailand.7
Deeper analysis: the Chinese randomised wrinkle trial (Wang and colleagues, 2013)
Wang and colleagues, at the Second Hospital of Xi'an Jiaotong University, reported the trial in the American Journal of Clinical Dermatology in 2013, noting that "the anti-wrinkle efficacy of argireline has not been studied in Chinese subjects".4 The stated objective was "to evaluate the safety and efficacy of argireline in the treatment of peri-orbital wrinkles in Chinese subjects".4 Sixty subjects were randomised 3:1 to argireline or placebo, applied to peri-orbital wrinkles twice daily for 4 weeks.4 Two measures were used: a subjective global assessment with "Daniell's classification and Seeman's standard", and an objective analysis of "silicone replicas of the skin at the application area" made before and after treatment.4 In the subjective evaluation "the total anti-wrinkle efficacy in the argireline group was 48.9 %, compared with 0 % in the placebo group".4 In the objective evaluation, "the parameters of roughness were all decreased in the argireline group", "while no decrease was obvious in the placebo group".4 The PubMed record does not give the argireline concentration, the number of people in each group, adverse-event figures (although safety is a stated objective), the funder or any author tie to a manufacturer, or the authors' limitations.4 The 2025 review describes this trial as a formulation "containing 10% acetyl hexapeptide-8" with "a 49% reduction in wrinkle depth" after 4 weeks of daily application, whereas the trial record reports 48.9% as total anti-wrinkle efficacy on a subjective global assessment and twice-daily application.5,4
Deeper analysis: NIH blepharospasm trial after botulinum toxin injection (NCT00942851)
The National Institute of Neurological Disorders and Stroke (NINDS) is the lead sponsor, with BCN Peptides, an industry organisation, listed as a collaborator, and the results section states "Pi Sponsor Employee: true".8 The design was randomised and triple-masked, with 24 people enrolled who had at least three prior successful botulinum toxin injection treatments "with stable interval between injections of 3 months".8 Participants applied cream "containing AH8 0.005%" or an identical cream without it twice daily to the eyelids from the day after an injection, and the registry states the hypothesis of "prolong the time until the need for the next injection by at least 3 months".8 The primary outcome was the "Time Until Jankovic Blepharospasm Rating Scale (JBRS) Reverts Back to Baseline"; the posted means were 3.71 months (SD 1.48) in 12 people on AH-8 and 3.03 months (SD .23) in 11 on placebo.8 The difference of about 0.7 months is below the 3 months the registry text hypothesised.8 Secondary outcomes at 3 months were a JBRS change of 1.09 (SD 0.7) with AH-8 against 0.92 (SD 2.07) with placebo, and a percentage change in the Blepharospasm Disability Scale of 30.89 (SD 37.3) against 32.32 (SD 31.13).8 No statistical comparison between arms appears in the posted results.8 One placebo participant left "due to unrelated personal problems", and four participants (two per arm) had "minor self-limited eyelid irritation", with no serious adverse events in either arm.8 No journal publication of this trial was identified among the PubMed records returned, so the registry entry is the source for the figures above.8
Deeper analysis: NIH dose-comparison blepharospasm trial (NCT01750346)
The same institute ran a phase 2 trial that the registry lists as "TERMINATED", enrolling 8 people against a planned 24, with no reason for stopping given in the entry.9 The registry gives the rationale that "the original dose studied was not very effective" and compares "0.025% and 0.05% AH-8" with placebo, twice daily, in people with primary blepharospasm who were at least 4 months off botulinum toxin and had no benefit from the last injection.9 The primary outcome was "the Jankovic Blepharospasm Rating Scale at month 2", where a higher score means more severe symptoms.9 Eight people started (3 on 0.05%, 2 on 0.025%, 3 on placebo) and 7 completed; one participant in the 0.05% arm "was withdrawn due to development of blepharitis".9 At 2 months the posted mean scores were 6 for 0.05% (2 people), 7 for 0.025% (2 people) and 4.33 for placebo (3 people), against baseline means of 7, 6 and 6.9 At 2 months the posted mean in the 0.025% arm (7) was above its baseline mean (6), the 0.05% arm's (6) was 1 point below its baseline mean (7), and the placebo arm's fell from 6 to 4.33; the 3-month secondary outcome gave posted means of 6.5 (0.05%, 2 people), 3 (0.025%, 2 people) and 2.33 (placebo, 3 people), in numbers this small.9 Serious adverse events were one automobile accident in the 0.05% arm, for which the entry notes the participant "reported that worsening of blepharospasm may have contributed to accident", and one case of blepharitis listed under placebo; the entry's own text also describes a blepharitis withdrawal in the 0.05% arm.9 Other listed events were puffiness of the lower eyelid and high blood pressure after missed blood pressure medication (each in the 0.05% arm), and tingling in both eyelids after cream application and weakness after botulinum toxin injection (each in the placebo arm).9 The sponsor is NINDS, the results contact lists "Pi Sponsor Employee: true", and the entry states no authors' limitations.9
Doses reported in studies and on labels
No prescribing label for argireline was identified; the DailyMed records returned by a search for acetyl hexapeptide-8 were listings for cosmetic creams, ampoules and solutions that contain it. The table lists the concentrations used in the studies above, with the app's 5–10% range for comparison.
| Source | Setting | Concentration and application | Duration | People |
|---|---|---|---|---|
| Blanes-Mira 20022 | Healthy women, emulsion | 10% hexapeptide, oil-in-water emulsion | 30 days | Not given in the record |
| Wang 20134 | Peri-orbital wrinkles, placebo-controlled | Twice daily; concentration not given in the record (a 2025 review gives 10%)5 | 4 weeks | 60 |
| NCT01381484, Mahidol7 | Face and periorbital area, placebo gel | 10% Argireline gel twice daily | 3 months | 70 |
| NCT02597777, UC Davis11 | Oily skin, half-face comparison with vehicle; entry lists no results | 10% AH-8 lotion on one half of the face, pea-size amount, twice daily | 4 weeks | 14 |
| NCT00942851, NINDS8 | Eyelids after botulinum toxin injection, placebo cream | 0.005% AH-8 cream twice daily | Up to 7 months | 24 |
| NCT01750346, NINDS9 | Eyelids, blepharospasm, placebo cream; terminated | 0.025% or 0.05% AH-8, twice daily | At least 3 months planned | 8 |
| Palmieri 202010 | Scars, skin tags, wrinkles; retrospective | Gel cream with 10% acetyl hexapeptide-8 on the lesion | Not given in the record | 26 |
| Kraeling 20151 | Laboratory, human cadaver and guinea pig skin | 10% in an oil-in-water emulsion at 2 mg/cm(2) | 24 hours | Not applicable |
| Cosmetic Ingredient Review Panel 20253 | Safety conclusion for cosmetics | Acetyl Hexapeptide-8 Amide safe in cosmetics in the present practices of use at concentrations up to 0.005%; data insufficient above 0.005% | Not applicable | Not applicable |
Sources in this part
Most wrinkle and skin trials above used 10%, within the app's 5–10% range, while the Cosmetic Ingredient Review Panel's safe conclusion covers concentrations up to 0.005% and its insufficient-data statement covers concentrations greater than 0.005%.3
Side effects reported
Blanes-Mira and colleagues report that the peptide "did not exhibit in vivo oral toxicity nor primary irritation at high doses", in a record that does not say in which animals or people.2 In the NIH after-injection blepharospasm trial, four of 24 participants, two per arm, had "minor self-limited eyelid irritation" and none had a serious adverse event.8 In the NIH dose-comparison trial of 8 people, the registry lists two serious events (an automobile accident in the 0.05% arm, with worsening of blepharospasm noted as a possible contributor, and blepharitis under placebo), a withdrawal of one 0.05% participant for blepharitis, and other events including puffiness of the lower eyelid (0.05% arm) and tingling of both eyelids after cream application (placebo arm, noted as an expected event).9 In a retrospective series of 26 patients using a gel cream with 10% acetyl hexapeptide-8, "no allergic reactions were documented during the period treatment".10 In cell experiments, Grosicki and colleagues (Jagiellonian University Medical College) tested argireline on human embryonic kidney HEK-293 cells, human neuroblastoma IMR-32 cells and human primary skin fibroblasts, reporting "dose-dependent argireline anti-proliferation effects".12 They report that "significant cytotoxicity of argireline solution was observed under 18 to 10 000 fold higher concentrations (depending on cells that were examined) in comparison to doxorubicin", and describe "an evident lack of reliable information about cytotoxicity of argireline in the literature".12 These are results in cultured cells, not in people.12
Regulatory and anti-doping status
Sources in this part
The Expert Panel for Cosmetic Ingredient Safety (Johnson and colleagues, International Journal of Toxicology, 2025) "concluded that Acetyl Hexapeptide-8 Amide is safe in cosmetics in the present practices of use at concentrations up to 0.005%".3 It further concluded that "the available data are insufficient to make a determination that Acetyl Hexapeptide-8 Amide is safe under the intended conditions of use in cosmetic formulations at concentrations greater than 0.005%".3 The PubMed record lists a research-support publication type, and a conflict statement declaring no potential conflicts of interest for the authors.3 The words "acetyl hexapeptide", "hexapeptide" and "argireline" do not appear in the text of the World Anti-Doping Agency's 2026 Prohibited List that was read, and no category on that list names it.14
What is not known
No half-life, blood concentration or time-to-peak measurement for topical argireline in people was returned by the PubMed and ClinicalTrials.gov searches, so the app's 4-hour half-life, 0.5-hour peak and 12-hour duration have no reported figure beside them.5 Whether the peptide reaches the neuromuscular junction after skin application "remains uncertain" according to the 2025 review.5 The in vitro skin penetration study detected no peptide in the dermis, which sits beside the app's 95% bioavailability figure and the proposed muscle-level mechanism without resolving either.1 The PubMed record of the Wang and colleagues trial omits group sizes, concentration and adverse events, and the registered Mahidol and UC Davis trials show no posted results in their entries.4,7,11 The two NIH blepharospasm trials enrolled 24 and 8 people, the dose-comparison trial was terminated, and neither registry entry posts a statistical comparison between arms.8,9 Kluczyk and colleagues (University of Wroclaw) analysed commercial products by mass spectrometry and report that "the analysis revealed the presence of argireline and its oxidized form in several different cosmetics", with the methionine residue indicated as the oxidation point.13 The safe concentration for cosmetic use above 0.005% has not been determined by the Cosmetic Ingredient Review Panel, which states its data are insufficient there.3
Frequently asked questions
Sources in this part
- 1Kraeling et al., 2015
- 2Blanes-Mira et al., 2002
- 3Johnson et al., 2025
- 4Wang et al., 2013
- 5Zdrada-Nowak et al., 2025
- 6Hoppel et al., 2015
- 7Mahidol University
- 8National Institute of Neurological Disorders and Stroke
- 9National Institute of Neurological Disorders and Stroke
- 10Palmieri et al., 2020
- 14World Anti-Doping Agency, 2026
What is Argireline?
What is the half-life of Argireline?
How much of Argireline is absorbed through the skin?
In an in vitro test on human cadaver skin, 0.22% of the applied dose was in the stratum corneum and 0.01% in the epidermis, while the app lists 95% bioavailability.1 The test used a 10% oil-in-water emulsion for 24 hours on excised skin, and a 2015 study in porcine skin found that emulsion type changed penetration.1,6
Is Argireline the same as Botox?
Does Argireline reduce wrinkles in trials?
Has Argireline been tested for blepharospasm?
What safety limit has the Cosmetic Ingredient Review set for Argireline?
What side effects have been reported with Argireline?
In the 24-person NIH trial, four people had "minor self-limited eyelid irritation", two on AH-8 and two on placebo.8 A retrospective series of 26 patients documented no allergic reactions, and the 8-person NIH trial lists two serious events (an automobile accident in the 0.05% arm and blepharitis under placebo), a withdrawal for blepharitis in the 0.05% arm, and eyelid puffiness and eyelid tingling among its other events.10,9
Is Argireline banned by WADA?
Argireline is not named in the text of the 2026 WADA Prohibited List that was read.14
Guides, tools and comparisons
References
- Kraeling ME, et al. In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutan Ocul Toxicol 2015. PMID 24754410
- Blanes-Mira C, et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci 2002. PMID 18498523
- Johnson W, et al. Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics. Int J Toxicol 2025. PMID 40673537
- Wang Y, et al. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol 2013. PMID 23417317
- Zdrada-Nowak J, et al. Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy. Int J Mol Sci 2025. PMID 40565185
- Hoppel M, et al. Topical delivery of acetyl hexapeptide-8 from different emulsions: influence of emulsion composition and internal structure. Eur J Pharm Sci 2015. PMID 25497319
- Mahidol University. Argireline in Treatment of Periorbital Wrinkles. ClinicalTrials.gov NCT01381484. NCT01381484
- National Institute of Neurological Disorders and Stroke. A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm. ClinicalTrials.gov NCT00942851. NCT00942851
- National Institute of Neurological Disorders and Stroke. Acetyl Hexapeptide-8 for Blepharospasm. ClinicalTrials.gov NCT01750346. NCT01750346
- Palmieri B, et al. Skin scars and wrinkles temporary camouflage in dermatology and oncoesthetics: focus on acetyl hexapeptide-8. Clin Ter 2020. PMID 33151254
- University of California, Davis. Topical Acetyl Hexapeptide-8 and the Cosmetic Appearance of Oily Skin. ClinicalTrials.gov NCT02597777. NCT02597777
- Grosicki M, et al. The study of cellular cytotoxicity of argireline - an anti-aging peptide. Acta Biochim Pol 2014. PMID 24644551
- Kluczyk A, et al. Argireline: Needle-Free Botox as Analytical Challenge. Chem Biodivers 2021. PMID 33482052
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list